Andean phytotherapy: systematic review of its application in prostate cancer
Keywords:
prostate, prostate neoplasia, phytotherapy, disease prevention, therapeutics.Abstract
Introduction: Prostate cancer is a serious problem in adult men. Although it is not a fatal disease, its incidence is increasing more and more. For recovery, different therapies are applied, among them phytotherapy becomes relevant.
Objective: Analyze phytotherapy techniques used in the Andean region for the prevention and treatment of prostate cancer.
Methods: A systematic review of the scientific evidence published from 2011 to 2021 was carried out; the following search terms were used: Urology, “Urology”; prostate cancer, “prostate cancer”; phytotherapy, “phytotherapy” and Andean phytotherapy, “Andean herbal medicine”. The databases consulted were: ISI - Web of Science, Science Direct, PubMed, SciELO and Google Scholar. In vitro/in vivo studies of animal and human models were included. Literature in a language other than Spanish was excluded.
Results: Eleven respective studies, submitted to the analysis, suggest satisfactory results at the experimental level. Likewise, endemic species of the Andean region such as Chuquiraga spinosa (chuquirahua), Xanthium spinosum (casha marucha), and Tropaeolum tuberosum (mashua) have shown promising results as an alternative and complementary treatment for urogenital conditions of the male population.
Conclusions: The plants studied according to phytotherapy in the Andean region seem promising for the prevention and treatment of prostate cancer, and it is suggested to use them together with conventional medicine. However, the research consulted is in the experimental phase, therefore, there are not yet sufficient elements for its recommendation.
Downloads
Download data is not yet available.
References
1. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018 [acceso 03/07/2021];8(12):a030361. Disponible en: https://www.perspectivesinmedicine.cshlp.org/content/8/12/a030361.short
2. Rawla P. Epidemiology of prostate Cancer. World J Oncol. 2019;10(2):63-89. DOI: https://doi.org/10.14740/wjon1191
3. Bhatt NR, Davis NF, Witjes WP, Bjartell A, Caris C, Patel A, et al. Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry. World J Urol. 2021 [acceso 10/07/2021];39(7):2661-7. Disponible en: https://link.springer.com/article/10.1007/s00345-020-03480-w
4. Repetto E, Sosa A, Martin Revol R, Metrebian E, Metrebian S. Relación de prostatitis en la aparición del cáncer de próstata y la hiperplasia benigna prostática. Rev Cubana Urol. 2019 [acceso 12/07/2021];8(1):22-33. Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/502
5. Leslie SW, Soon Sutton TL, Sajjad H, Siref LE. Prostate Cancer. En: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021 [acceso 15/07/2021]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK470550/
6. Shivajirao CS, B.Bawage S, B.Bawage N. Herbal medicine and its uses. IJRPR. 2021 [acceso 25/07/2021];2(10):949-50. Disponible en: https://ijrpr.com/uploads/V2ISSUE10/IJRPR1600.pdf
7. Soria N. Las plantas medicinales y su aplicación en la salud pública. Rev Salud Pública Parag. 2018;8(1):7-8. DOI: https://doi.org/10.18004/rspp.2018.junio.7-8
8. Bounda GA. Phytotherapy of prostate cancer: how far are we? Clin Oncol Case Rep. 2018 [acceso 12/08/2021];1(1). Disponible en: https://www.scitechnol.com/peer-review/phytotherapy-of-prostate-cancerhow-far-are-we-IzBq.php?article_id=7710
9. Seisen T, Drouin SJ, Rouprêt M. Hipertrofia benigna de próstata. EMC - Tratado de Medicina. 2017; 21(2):1-10. DOI: https://www.doi.org/10.1016/S1636-5410(17)84251-3
10. Aguaiza Quizhpilema J, Simbaina Solano JC. Uso de plantas medicinales y conocimientos ancestrales en las comunidades rurales de la provincia de Cañar, Ecuador. Rev CENIC Cienc Biol. 2021 [acceso 09/09/2021];52(3):223-36. Disponible en: https://revista.cnic.edu.cu/index.php/RevBiol/article/view/1210
11. El-Readi MZ, Al-Abd AM, Althubiti MA, Almaimani RA, Al-Amoodi HS, Ashour ML, et al. Multiple molecular mechanisms to overcome multidrug resistance in cancer by natural secondary metabolites. Front Pharmacol. 2021; 12:942. DOI: https://doi.org/10.3389/fphar.2021.658513
12. Tarkang PA, Appiah Opong R, Ofori MF, Ayong LS, Nyarko AK. Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification. Biomark Res. 2016 [acceso 26/12/2021];4(1):25. Disponible en: https://link.springer.com/article/10.1186/s40364-016-0077-0
13. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol. 2020; 10:1614. DOI: https://doi.org/10.3389/fphar.2019.01614
14. Stolarczyk M, Piwowarski JP, Granica S, Stefańska J, Naruszewicz M, Kiss AK. Extracts from epilobium sp. herbs, their components and gut microbiota metabolites of epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion. Phytother Res. 2013; 27(12):1842-8. DOI: https://doi.org/10.1002/ptr.4941
15. Wehrberger C, Dreikorn K, Schmitz Dräger BJ, Oelke M, Madersbacher S. Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo. Urologe A. 2012 [acceso 03/01/2022]; 51(12):1674-82. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23160605/
16. Elterman DS, Lawrentschuk N, Guns E, Hersey K, Adomat H, Wood CA, et al. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with α-blockers and 5α-reductase inhibitors. J Urol. 2010; 183(5):2085-9. DOI: https://doi.org/10.1016/j.juro.2009.12.097
17. Kim SM, Park JH, Kim KD, Nam D, Shim BS, Kim SH, et al. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades. Phytother Res. 2014;28(3):423-31. DOI: https://doi.org/10.1002/ptr.5010
18. Asare GA, Ngala RA, Afriyie D, Adjei S, Nyarko A, Anang Quartey Y, et al. Calcium - magnesium imbalance implicated in benign prostatic hyperplasia and restoration by a phytotherapeutic drug – Croton membranaceus Müll.Arg. BMC Complement Altern Med. 2017 [acceso 05/01/2022]; 17(1):152. Disponible en: https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-017-1663-x
19. Deveci E, Cayan GT, Karakurt S, Duru ME. Antioxidant, cytotoxic, and enzyme inhibitory activities of agropyron repens and crataegus monogyna species. Eur J Biol. 2020 [acceso 06/01/2022];79(2):98-105. Disponible en: https://dergipark.org.tr/en/pub/iufsjb/issue/55111/844411
20. Arroyo Acevedo J, Herrera Calderón O, Chávez Asmat R, Anampa Guzmán A, Chumpitaz Cerrate V, Enciso Roca E. Protective effect of Chuquiraga spinosa extract on N-methyl-nitrosourea (NMU) induced prostate cancer in rats. Prostate Int. 2017; 5(2):47-52. DOI: https://doi.org/10.1016/j.prnil.2017.01.005
21. Guerrero Bonilla DA, Granda Albuja MG, Guevara M, Iturralde GA, Jaramillo Vivanco T, Giampieri F, et al. Bioactive compounds and antioxidant capacity of Chuquiraga jussieui J.F.Gmel from the highlands of Ecuador. Nat Prod Res. 2020;34(18):2652-5. DOI: https://doi.org/10.1080/14786419.2018.1548450
22. Verma V, Sharma V, Singh V, Kumar R, Khan MF, Singh AK, et al. Labda-8(17),12,14-trien-19-oic acid contained in fruits of Cupressus sempervirens suppresses benign prostatic hyperplasia in rat and in vitro human models through inhibition of androgen and STAT-3 signaling. Phytother Res. 2014;28(8):1196-203. DOI: https://doi.org/10.1002/ptr.5114
23. Boeing T, Tafarelo Moreno KG, Gasparotto Junior A, Mota da Silva L, de Souza P. Phytochemistry and pharmacology of the genus equisetum (equisetaceae): A narrative review of the species with therapeutic potential for kidney diseases. J Evid Based Complementary Altern Med. 2021; 2021: e6658434. DOI: https://doi.org/10.1155/2021/6658434
24. Mahboubi M. Urtica dioica in the management of benign prostate hyperplasia (BPH). J Nat Prod. 2019;10(5):535-42. DOI: https://doi.org/10.2174/2210315509666190723125509
25. Güez CM, Waczuk EP, Pereira KB, Querol MVM, Rocha JBT da, de Oliveira LFS. In vivo and in vitro genotoxicity studies of aqueous extract of Xanthium spinosum. Braz J Pharm Sci. 2012;48:461-7. DOI: https://doi.org/10.1590/S1984-82502012000300013
26. Xu YM, Wijeratne EMK, Babyak AL, Marks HR, Brooks AD, Tewary P, et al. Withanolides from aeroponically grown Physalis peruviana and their selective cytotoxicity to prostate cancer and renal carcinoma cells. J Nat Prod. 2017; 80(7):1981-91. DOI: https://doi.org/10.1021/acs.jnatprod.6b01129
27. Karimi E, Oskoueian E, Karimi A, Noura R, Ebrahimi M. Borago officinalis L. flower: a comprehensive study on bioactive compounds and its health-promoting properties. J Food Meas Charact. 2018 [acceso 08/01/2022];12(2):826-38. Disponible en: https://link.springer.com/article/10.1007/s11694-017-9697-9
28. Chung KS, Shin SJ, Lee NY, Cheon SY, Park W, Sun SH, et al. Anti-proliferation effects of garlic (Allium sativum L.) on the progression of benign prostatic hyperplasia. Phytother Res. 2016;30(7):1197-203. DOI: https://doi.org/10.1002/ptr.5637
29. Flores E, Apaza J, Calsina WC, Quille G, Huanca F, Coloma A, et al. Conocimiento ancestral en la curación de la próstata a base de isaño (Tropaeolum tuberosum). Idesia (Arica). 2020;38(4):7-16. DOI: https://doi.org/10.4067/S0718-34292020000400007
2. Rawla P. Epidemiology of prostate Cancer. World J Oncol. 2019;10(2):63-89. DOI: https://doi.org/10.14740/wjon1191
3. Bhatt NR, Davis NF, Witjes WP, Bjartell A, Caris C, Patel A, et al. Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry. World J Urol. 2021 [acceso 10/07/2021];39(7):2661-7. Disponible en: https://link.springer.com/article/10.1007/s00345-020-03480-w
4. Repetto E, Sosa A, Martin Revol R, Metrebian E, Metrebian S. Relación de prostatitis en la aparición del cáncer de próstata y la hiperplasia benigna prostática. Rev Cubana Urol. 2019 [acceso 12/07/2021];8(1):22-33. Disponible en: http://www.revurologia.sld.cu/index.php/rcu/article/view/502
5. Leslie SW, Soon Sutton TL, Sajjad H, Siref LE. Prostate Cancer. En: StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2021 [acceso 15/07/2021]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK470550/
6. Shivajirao CS, B.Bawage S, B.Bawage N. Herbal medicine and its uses. IJRPR. 2021 [acceso 25/07/2021];2(10):949-50. Disponible en: https://ijrpr.com/uploads/V2ISSUE10/IJRPR1600.pdf
7. Soria N. Las plantas medicinales y su aplicación en la salud pública. Rev Salud Pública Parag. 2018;8(1):7-8. DOI: https://doi.org/10.18004/rspp.2018.junio.7-8
8. Bounda GA. Phytotherapy of prostate cancer: how far are we? Clin Oncol Case Rep. 2018 [acceso 12/08/2021];1(1). Disponible en: https://www.scitechnol.com/peer-review/phytotherapy-of-prostate-cancerhow-far-are-we-IzBq.php?article_id=7710
9. Seisen T, Drouin SJ, Rouprêt M. Hipertrofia benigna de próstata. EMC - Tratado de Medicina. 2017; 21(2):1-10. DOI: https://www.doi.org/10.1016/S1636-5410(17)84251-3
10. Aguaiza Quizhpilema J, Simbaina Solano JC. Uso de plantas medicinales y conocimientos ancestrales en las comunidades rurales de la provincia de Cañar, Ecuador. Rev CENIC Cienc Biol. 2021 [acceso 09/09/2021];52(3):223-36. Disponible en: https://revista.cnic.edu.cu/index.php/RevBiol/article/view/1210
11. El-Readi MZ, Al-Abd AM, Althubiti MA, Almaimani RA, Al-Amoodi HS, Ashour ML, et al. Multiple molecular mechanisms to overcome multidrug resistance in cancer by natural secondary metabolites. Front Pharmacol. 2021; 12:942. DOI: https://doi.org/10.3389/fphar.2021.658513
12. Tarkang PA, Appiah Opong R, Ofori MF, Ayong LS, Nyarko AK. Application of multi-target phytotherapeutic concept in malaria drug discovery: a systems biology approach in biomarker identification. Biomark Res. 2016 [acceso 26/12/2021];4(1):25. Disponible en: https://link.springer.com/article/10.1186/s40364-016-0077-0
13. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol. 2020; 10:1614. DOI: https://doi.org/10.3389/fphar.2019.01614
14. Stolarczyk M, Piwowarski JP, Granica S, Stefańska J, Naruszewicz M, Kiss AK. Extracts from epilobium sp. herbs, their components and gut microbiota metabolites of epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion. Phytother Res. 2013; 27(12):1842-8. DOI: https://doi.org/10.1002/ptr.4941
15. Wehrberger C, Dreikorn K, Schmitz Dräger BJ, Oelke M, Madersbacher S. Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo. Urologe A. 2012 [acceso 03/01/2022]; 51(12):1674-82. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23160605/
16. Elterman DS, Lawrentschuk N, Guns E, Hersey K, Adomat H, Wood CA, et al. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with α-blockers and 5α-reductase inhibitors. J Urol. 2010; 183(5):2085-9. DOI: https://doi.org/10.1016/j.juro.2009.12.097
17. Kim SM, Park JH, Kim KD, Nam D, Shim BS, Kim SH, et al. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades. Phytother Res. 2014;28(3):423-31. DOI: https://doi.org/10.1002/ptr.5010
18. Asare GA, Ngala RA, Afriyie D, Adjei S, Nyarko A, Anang Quartey Y, et al. Calcium - magnesium imbalance implicated in benign prostatic hyperplasia and restoration by a phytotherapeutic drug – Croton membranaceus Müll.Arg. BMC Complement Altern Med. 2017 [acceso 05/01/2022]; 17(1):152. Disponible en: https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-017-1663-x
19. Deveci E, Cayan GT, Karakurt S, Duru ME. Antioxidant, cytotoxic, and enzyme inhibitory activities of agropyron repens and crataegus monogyna species. Eur J Biol. 2020 [acceso 06/01/2022];79(2):98-105. Disponible en: https://dergipark.org.tr/en/pub/iufsjb/issue/55111/844411
20. Arroyo Acevedo J, Herrera Calderón O, Chávez Asmat R, Anampa Guzmán A, Chumpitaz Cerrate V, Enciso Roca E. Protective effect of Chuquiraga spinosa extract on N-methyl-nitrosourea (NMU) induced prostate cancer in rats. Prostate Int. 2017; 5(2):47-52. DOI: https://doi.org/10.1016/j.prnil.2017.01.005
21. Guerrero Bonilla DA, Granda Albuja MG, Guevara M, Iturralde GA, Jaramillo Vivanco T, Giampieri F, et al. Bioactive compounds and antioxidant capacity of Chuquiraga jussieui J.F.Gmel from the highlands of Ecuador. Nat Prod Res. 2020;34(18):2652-5. DOI: https://doi.org/10.1080/14786419.2018.1548450
22. Verma V, Sharma V, Singh V, Kumar R, Khan MF, Singh AK, et al. Labda-8(17),12,14-trien-19-oic acid contained in fruits of Cupressus sempervirens suppresses benign prostatic hyperplasia in rat and in vitro human models through inhibition of androgen and STAT-3 signaling. Phytother Res. 2014;28(8):1196-203. DOI: https://doi.org/10.1002/ptr.5114
23. Boeing T, Tafarelo Moreno KG, Gasparotto Junior A, Mota da Silva L, de Souza P. Phytochemistry and pharmacology of the genus equisetum (equisetaceae): A narrative review of the species with therapeutic potential for kidney diseases. J Evid Based Complementary Altern Med. 2021; 2021: e6658434. DOI: https://doi.org/10.1155/2021/6658434
24. Mahboubi M. Urtica dioica in the management of benign prostate hyperplasia (BPH). J Nat Prod. 2019;10(5):535-42. DOI: https://doi.org/10.2174/2210315509666190723125509
25. Güez CM, Waczuk EP, Pereira KB, Querol MVM, Rocha JBT da, de Oliveira LFS. In vivo and in vitro genotoxicity studies of aqueous extract of Xanthium spinosum. Braz J Pharm Sci. 2012;48:461-7. DOI: https://doi.org/10.1590/S1984-82502012000300013
26. Xu YM, Wijeratne EMK, Babyak AL, Marks HR, Brooks AD, Tewary P, et al. Withanolides from aeroponically grown Physalis peruviana and their selective cytotoxicity to prostate cancer and renal carcinoma cells. J Nat Prod. 2017; 80(7):1981-91. DOI: https://doi.org/10.1021/acs.jnatprod.6b01129
27. Karimi E, Oskoueian E, Karimi A, Noura R, Ebrahimi M. Borago officinalis L. flower: a comprehensive study on bioactive compounds and its health-promoting properties. J Food Meas Charact. 2018 [acceso 08/01/2022];12(2):826-38. Disponible en: https://link.springer.com/article/10.1007/s11694-017-9697-9
28. Chung KS, Shin SJ, Lee NY, Cheon SY, Park W, Sun SH, et al. Anti-proliferation effects of garlic (Allium sativum L.) on the progression of benign prostatic hyperplasia. Phytother Res. 2016;30(7):1197-203. DOI: https://doi.org/10.1002/ptr.5637
29. Flores E, Apaza J, Calsina WC, Quille G, Huanca F, Coloma A, et al. Conocimiento ancestral en la curación de la próstata a base de isaño (Tropaeolum tuberosum). Idesia (Arica). 2020;38(4):7-16. DOI: https://doi.org/10.4067/S0718-34292020000400007
Downloads
Published
2022-05-16
How to Cite
1.
Simbaina Solano JC, Solano Pichazaca RJ. Andean phytotherapy: systematic review of its application in prostate cancer. Rev. Cubana Urol. [Internet]. 2022 May 16 [cited 2024 Nov. 24];11(2):16-25. Available from: https://revurologia.sld.cu/index.php/rcu/article/view/805
Issue
Section
Revisiones bibliográficas
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cual estará simultáneamente sujeto a la Licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
